Reducing cognitive decline in patients with mild cognitive impairment and Alzheimer's Disease and related dementias by developing and testing clinician and caregiver deprescribing tools

通过开发和测试临床医生和护理人员处方工具,减少轻度认知障碍、阿尔茨海默氏病和相关痴呆症患者的认知能力下降

基本信息

项目摘要

Worsening cognitive decline is a hallmark problem in patients with mild cognitive impairment (MCI) and Alzheimer’s Disease and related dementias (ADRD). Despite the well-recognized worsening of cognitive burden by high-risk medications like benzodiazepines, medications with strong anticholinergic side effects, and sedative hypnotics, they continue to be overprescribed in this population. Many factors contribute to their overuse including clinical inertia and the need to involve caregivers. Fortunately, deprescribing has been shown to improve outcomes in patients with MCI/ADRD. However, deprescribing efforts have often had modest success due to lack of primary care provider (PCP) involvement and giving insufficient support at the point of care. Interventions that have been successful have been resource intensive and thus difficult to scale. In contrast, electronic health record (EHR) systems offer a scalable strategy for changing provider behavior that could be useful for deprescribing medications that worsen cognitive burden. Existing literature demonstrates the potential for EHR-based tools to improve deprescribing, especially when augmented with insights from behavioral science. EHR systems could also be leveraged to engage caregivers in the deprescribing process but has not been done before. Despite the high potential for scalability, application of specific deprescribing tools in EHRs for PCPs has been limited, especially for MCI/ADRD populations. To overcome this gap, we propose this R21 to develop and pilot test new EHR deprescribing tools for PCPs of patients with MCI/ADRD that also involve caregivers. We will leverage learnings from our NUDGE- EHR trial, an NIA-funded pragmatic trial evaluating whether EHR tools designed using behavioral science improves deprescribing in general older adults and adapt them for the MCI/ADRD population to provide pilot data for a subsequent large pragmatic trial and generalizable evidence about caregiver engagement strategies. The specific aims are: (1) to design and pilot test EHR tools using behavioral science for deprescribing in patients with MCI/ADRD and (2) to identify strategies for engaging caregivers in EHR tools. The new tools will include a PCP-facing EHR dashboard that identifies patients in need of deprescribing and facilitates communication with caregivers, alerts enhanced with behavioral principles to encourage deprescribing, order sets that provide easier ordering of dose-tapers and alternative medications, and post-visit monitoring tools. We will conduct qualitative interviews and pilot testing within the EHR system with PCPs and caregivers to demonstrate feasibility and usability of the EHR tools, also assessing implementation outcomes to identify barriers to intervention scalability. In addition, we will evaluate the ability to engage caregivers using caregiver- facing surveys delivered through EHR patient portal, emailed, phone, and mailed communications. The expected overall impact of this innovative proposal is that it will advance how EHRs can be optimized to improve prescribing for patients with MCI/ADRD to improve cognitive burden in ways that are highly scalable.
认知功能下降恶化是轻度认知功能障碍(MCI)患者的标志性问题, 阿尔茨海默病和相关痴呆症(ADRD)。尽管认知功能的恶化是众所周知的, 高风险药物如苯二氮卓类药物,具有强烈抗胆碱能副作用的药物, 镇静催眠药,他们继续在这个人群中被过度使用。许多因素有助于他们的 过度使用,包括临床惰性和需要护理人员参与。幸运的是, 改善MCI/ADRD患者的预后。然而,取消处方的努力往往 由于缺乏初级保健提供者(PCP)的参与,以及在 护理点。成功的干预措施都是资源密集型的,因此难以推广。 相比之下,电子健康记录(EHR)系统为不断变化的提供者提供了可扩展的策略 这些行为可能有助于取消那些加重认知负担的药物。现有文献 证明了基于EHR的工具在改善取消处方方面的潜力,特别是在增加 行为科学的见解。EHR系统也可以用来让护理人员参与 这是一个取消的过程,但以前没有这样做过。尽管具有很高的可扩展性潜力, 在PCP的EHR中,特别是对于MCI/ADRD人群,特定的开药工具有限。 为了克服这一差距,我们建议这个R21开发和试点测试新的EHR取消处方工具, MCI/ADRD患者的PCP也涉及护理人员。我们将从我们的NUDGE学习, EHR试验,一项由NIA资助的实用性试验,评估EHR工具是否使用行为科学设计 改善一般老年人的处方,并使其适应MCI/ADRD人群,以提供试点 数据为随后的大型务实的试验和概括的证据照顾者的参与战略。 具体目标是:(1)利用行为科学设计和试点测试EHR工具, MCI/ADRD患者;(2)确定使护理人员参与EHR工具的策略。新工具将 包括一个面向PCP的EHR仪表板,用于识别需要取消处方的患者, 与护理人员沟通,通过行为原则增强警报,以鼓励取消处方, 提供更容易订购剂量递减和替代药物的套件,以及访视后监测工具。 我们将在EHR系统内与PCP和护理人员进行定性访谈和试点测试, 证明EHR工具的可行性和可用性,并评估实施结果,以确定 干预可扩展性的障碍。此外,我们还将评估使用护理人员- 面对通过EHR患者门户、电子邮件、电话和邮寄通信交付的调查。的 这一创新提案的预期总体影响是,它将推动如何优化EHR, 改善MCI/ADRD患者的处方,以高度可扩展的方式改善认知负担。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julie Christine Lauffenburger其他文献

Julie Christine Lauffenburger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julie Christine Lauffenburger', 18)}}的其他基金

Development of a novel medication adherability tool to improve cardiovascular disease management
开发新型药物依从性工具以改善心血管疾病管理
  • 批准号:
    10132378
  • 财政年份:
    2018
  • 资助金额:
    $ 51.1万
  • 项目类别:
Development of a novel medication adherability tool to improve cardiovascular disease management
开发新型药物依从性工具以改善心血管疾病管理
  • 批准号:
    9886260
  • 财政年份:
    2018
  • 资助金额:
    $ 51.1万
  • 项目类别:
Development of a novel medication adherability tool to improve cardiovascular disease management
开发新型药物依从性工具以改善心血管疾病管理
  • 批准号:
    10375402
  • 财政年份:
    2018
  • 资助金额:
    $ 51.1万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 51.1万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 51.1万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 51.1万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 51.1万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了